Podophyllotoxin
Brand names: Warticon, Condyline
Podophyllotoxin is a topical antimitotic agent used for external anogenital warts.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It binds tubulin and arrests cell division in metaphase, causing necrosis of the wart tissue.
Prescribing in practice
- It is contraindicated in pregnancy because of potential toxicity, and effective contraception should be ensured in those who could become pregnant.
- Apply precisely to the wart, protecting surrounding healthy skin, and respect the limit on the area treated per application to reduce systemic absorption and local irritation.
- Treatment is given in cycles of several days followed by a rest period, repeated as directed; local irritation, erosion and soreness are common.
Monitoring
Review treated warts for response and the surrounding skin for irritation, and reassess if warts persist after the recommended cycles.
Counselling the patient
- Do not use if you are or might be pregnant.
- Apply only to the warts and protect the normal skin around them.
- Follow the treat-and-rest cycle exactly as instructed and expect some soreness.
Evidence & guidelines
Podophyllotoxin is a recognised patient-applied first-line treatment option for external anogenital warts in UK and dermatology guidance.
Reference: BASHH Anogenital Warts Guidelines 2015; NICE CKS Genital Warts; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD